These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. [Testing of vaccines. The challenge of testing complex combination vaccines]. Merkle A; Lechner H; Oppling V; Meyer H Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1188-92. PubMed ID: 25204275 [TBL] [Abstract][Full Text] [Related]
8. [Batch release of immunoglobulin and monoclonal antibody products]. Gross S Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1185-7. PubMed ID: 25200488 [TBL] [Abstract][Full Text] [Related]
9. Recommendations regarding technical standards for follow-on biologics: comparability, similarity, interchangeability. Davis GC; Beals JM; Johnson C; Mayer MH; Meiklejohn BI; Mitlak BH; Roth JL; Towns JK; Veenhuizen M Curr Med Res Opin; 2009 Jul; 25(7):1655-61. PubMed ID: 19476407 [TBL] [Abstract][Full Text] [Related]
10. Concept of biosimilar products in Jordan. Haddadin RD Biologicals; 2011 Sep; 39(5):333-5. PubMed ID: 21873079 [TBL] [Abstract][Full Text] [Related]
11. Characterizing biological products and assessing comparability following manufacturing changes. Chirino AJ; Mire-Sluis A Nat Biotechnol; 2004 Nov; 22(11):1383-91. PubMed ID: 15529163 [TBL] [Abstract][Full Text] [Related]
12. [Experimental testing of centrally authorised medicinal products. The CAP programme]. Giess S Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1169-72. PubMed ID: 25159224 [TBL] [Abstract][Full Text] [Related]
13. [Approval of drugs by national and European agencies--sequelae for the pharmaceutical industry]. Zierenberg O Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):596-600. PubMed ID: 9527448 [TBL] [Abstract][Full Text] [Related]
14. Legislative initiatives in Europe, Canada and the US for market authorization of follow-on biologics. Looper YJ Curr Opin Drug Discov Devel; 2010 Mar; 13(2):247-56. PubMed ID: 20205058 [TBL] [Abstract][Full Text] [Related]
15. Current regulatory and scientific considerations for approving biosimilars in Iran. Hadavand N; Valadkhani M; Zarbakhsh A Biologicals; 2011 Sep; 39(5):325-7. PubMed ID: 21873077 [TBL] [Abstract][Full Text] [Related]
16. [Reduction of animal experiments in experimental drug testing]. Behrensdorf-Nicol H; Krämer B Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1173-80. PubMed ID: 25183445 [TBL] [Abstract][Full Text] [Related]
17. [Effect of the German Act on the reform of the market for medicinal products (AMNOG) on the quality of neurological and psychiatric treatment]. Hamer H; Meyer-Lindenberg A Nervenarzt; 2016 Apr; 87(4):351-2. PubMed ID: 27025218 [No Abstract] [Full Text] [Related]
18. Model competencies in regulatory therapeutic product assessment: Health Canada's good review guiding principles as a reviewing community's code of intellectual conduct. Lim RR Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):933-41. PubMed ID: 17290483 [TBL] [Abstract][Full Text] [Related]
19. [Earlier value assessment of pharmaceutical products and medical science]. Selbmann HK Nervenarzt; 2016 Apr; 87(4):353-5. PubMed ID: 27000270 [No Abstract] [Full Text] [Related]
20. Food and Drug Administration regulation and evaluation of vaccines. Marshall V; Baylor NW Pediatrics; 2011 May; 127 Suppl 1():S23-30. PubMed ID: 21502242 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]